MedTrace Logo

Attexis and tDCS for the Treatment of ADHD

NCT06766214 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2026-02-27

No results posted yet for this study

Summary

A randomized controlled two-arm study (RCT) will be conducted. It is planned to randomly assign eligible patients who receive a three-month access to the psychotherapeutic program (Attexis) to either an additional verum-tDCS or placebo-tDCS condition.

Conditions

  • ADHD

Interventions

DEVICE

transcranial direct current stimulation

Simultaneous treatment with tDCS and online-based psychotherapy

DEVICE

sham transcranial direct current stimulation

Simultaneous treatment with sham-tDCS and online-based psychotherapy

Sponsors & Collaborators

  • Sooma Medical

    collaborator UNKNOWN

  • Gaia AG

    collaborator INDUSTRY

  • University of Regensburg

    lead OTHER

Principal Investigators

  • Berthold Langguth, PhD · University of Regensburg

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-09-01
Primary Completion
2025-11-21
Completion
2026-02-24

Countries

  • Germany

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06766214 on ClinicalTrials.gov